Tricida Inc (NASDAQ:TCDA) CEO Gerrit Klaerner sold 4,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $39.49, for a total value of $157,960.00. Following the completion of the transaction, the chief executive officer now owns 590,841 shares in the company, valued at approximately $23,332,311.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Gerrit Klaerner also recently made the following trade(s):
- On Friday, November 29th, Gerrit Klaerner sold 2,000 shares of Tricida stock. The shares were sold at an average price of $39.80, for a total value of $79,600.00.
- On Monday, October 28th, Gerrit Klaerner sold 4,000 shares of Tricida stock. The stock was sold at an average price of $37.41, for a total value of $149,640.00.
- On Monday, September 30th, Gerrit Klaerner sold 10,255 shares of Tricida stock. The shares were sold at an average price of $30.69, for a total value of $314,725.95.
NASDAQ TCDA opened at $39.59 on Wednesday. The stock has a market capitalization of $1.98 billion, a P/E ratio of -8.53 and a beta of 0.86. Tricida Inc has a 52-week low of $19.43 and a 52-week high of $42.80. The firm has a 50-day moving average price of $37.62 and a 200 day moving average price of $35.01. The company has a quick ratio of 15.48, a current ratio of 15.48 and a debt-to-equity ratio of 0.15.
Hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Tricida in the 3rd quarter valued at approximately $29,000. Bank of Montreal Can acquired a new position in Tricida during the second quarter worth $72,000. Tower Research Capital LLC TRC acquired a new position in Tricida during the third quarter worth $57,000. Nisa Investment Advisors LLC purchased a new position in Tricida in the third quarter worth $145,000. Finally, Strs Ohio raised its position in Tricida by 8.3% in the second quarter. Strs Ohio now owns 5,200 shares of the company’s stock worth $205,000 after acquiring an additional 400 shares in the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on TCDA shares. ValuEngine upgraded Tricida from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Cowen set a $50.00 price objective on shares of Tricida and gave the company a “buy” rating in a research report on Tuesday, October 15th. Needham & Company LLC set a $50.00 price objective on shares of Tricida and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Zacks Investment Research cut shares of Tricida from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $49.60.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.